Status:
UNKNOWN
Sentinel Lymph Node Mapping In Endometrial Cancer
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Chinese Academy of Medical Sciences
Peking University International Hospital
Conditions:
Endometrial Neoplasms
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Lymph node assessment provides the crucial information about the prognosis of endometrial cancer. Sentinel lymph node stands in the first station on the lymph node metastasis pathways. While tradition...
Detailed Description
Quality Control The investigators' quality assurance plan is as follows. A. Once the plan has been approved, it cannot be modified at will. If special circumstances such as difficulty in implementatio...
Eligibility Criteria
Inclusion
- Diagnosis of endometrial cancer (including all pathological type and clinical stage).
- Decide to receive hysterectomy with or without bilateral adnexectomy, pelvic and para-aortic lymph node resection
- Agree to conduct the study and sign an informed consent form
Exclusion
- History of previous pelvic or inguinal lymphadenectomy or other history of surgery affecting the uterine lymphatic drainage
- Other history of pelvic or abdominal malignant tumors in the past 5 years
- Intolerable for surgery due to severe comorbidities
- During a period of pregnancy
- Allergic to the tracer
- Diagnosis of uncontrolled epilepsy, central nervous system disease or mental disorder, with the judgment from the investigator that the above diseases would affect clinical research compliance.
Key Trial Info
Start Date :
December 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2020
Estimated Enrollment :
635 Patients enrolled
Trial Details
Trial ID
NCT03778255
Start Date
December 15 2018
End Date
June 30 2020
Last Update
December 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hosoital
Beijing, Beijing Municipality, China, 100044